Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Eurovision
Pope Leo XIV
Pope Francis
Social Media
Premier League
Inauguration
South America
Israel-Hamas Conflict
European Union
Motorsports
Formula 1
Artificial Intelligence
Published • loading... • Updated

MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial

Summary by hcplive.com
MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

3 Articles

All
Left
Center
2
Right
Hastings TribuneHastings Tribune
Reposted by
The Daily NewsThe Daily News
Center

Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 7, 2025-

Read Full Article
hcplive.comhcplive.com

MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial

MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Daily News broke the news in on Wednesday, May 7, 2025.
Sources are mostly out of (0)

Similar News Topics

South San Francisco

South San Francisco

News
For You
SearchBlindspotLocal